Mikalena Xenophontos
Mikalena Xenophontos has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Assie O’COnnor
Haywood Academic Rheumatology Centre, Midlands Partnership University NHS Foundation Trust , Staffordshire
1 shared publicationBruce W Kirkham
Department of Rheumatology, Guy's and St Thomas’ NHS Foundation Trust, London, UK
1 shared publication- Christian David Mallen
Keele Staffordshire ST5 5BG School of Medicine and Centre for Musculoskeletal Health Research , Keele University
1 shared publication Christopher Barker
Community Pain Management Service, Mersey Care NHS Foundation Trust
1 shared publicationChristopher D Buckley
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication- Christopher Dominic Buckley
Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis
Pain is a frequent symptom in people with inflammatory arthritis (IA), which has substantial impact on their quality of life. Analyses of electronic health record data indicate that UK pain care in people with IA often involves prescribing long-term opioids and gabapentinoids, despite absent trial evidence for efficacy. Patient survey data suggest that non-pharmacological pain care with supportive trial evidence is underused. A UK-specific guideline on pain management for people with IA is required to address this. This comprehensive life-course guideline is the first British Society for Rheumatology Guideline to specifically address pain in people with IA. It provides evidence-based recommendations on how pain can be best managed in people with IA. It was developed using the methods outlined in the British Society for Rheumatology’s ‘Creating Clinical Guidelines’ protocol by a multidisciplinary Guideline Working Group, comprising healthcare professionals with expertise in paediatric and adult rheumatology and people with lived experience. By undertaking and considering the evidence from several systematic literature and umbrella reviews, 23 recommendations were developed. These address how pain should be assessed in people with IA alongside the role of the following treatments in IA pain management: DMARDs, glucocorticoids, analgesics, neuromodulators, exercise and physical activity, psychological interventions, ergonomic and orthotic interventions (excluding orthoses for foot pain), education, weight management and diet, addressing sleep problems, fatigue management, digital technologies and medical devices, complementary therapies, and support from others. An audit tool is provided to support the Guideline’s implementation, and key recommendations made for future research.
- 30 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Open AccessThe 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis
Pain is a frequent symptom in people with inflammatory arthritis (IA), which has substantial impact on their quality of life. Analyses of electronic health record data indicate that UK pain care in people with IA often involves prescribing long-term opioids and gabapentinoids, despite absent trial evidence for efficacy. Patient survey data suggest that non-pharmacological pain care with supportive trial evidence is underused. A UK-specific guideline on pain management for people with IA is required to address this. This comprehensive life-course guideline is the first British Society for Rheumatology Guideline to specifically address pain in people with IA. It provides evidence-based recommendations on how pain can be best managed in people with IA. It was developed using the methods outlined in the British Society for Rheumatology’s ‘Creating Clinical Guidelines’ protocol by a multidisciplinary Guideline Working Group, comprising healthcare professionals with expertise in paediatric and adult rheumatology and people with lived experience. By undertaking and considering the evidence from several systematic literature and umbrella reviews, 23 recommendations were developed. These address how pain should be assessed in people with IA alongside the role of the following treatments in IA pain management: DMARDs, glucocorticoids, analgesics, neuromodulators, exercise and physical activity, psychological interventions, ergonomic and orthotic interventions (excluding orthoses for foot pain), education, weight management and diet, addressing sleep problems, fatigue management, digital technologies and medical devices, complementary therapies, and support from others. An audit tool is provided to support the Guideline’s implementation, and key recommendations made for future research.
- Open Access
- 11 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?
Fibroblasts constitute a major component of our stroma, the supportive bedding in which our tissues reside. The introduction of advanced single-cell technologies has greatly enhanced our appreciation of fibroblast heterogeneity in health and immune-mediated inflammatory diseases (IMIDs). This heterogeneity correlates with their diverse functions, including providing architectural support, tissue identity, ‘stromal memory’, and regulating immune responses and fibrosis. In RA, fibroblasts contribute to both synovial inflammation and bone and cartilage damage, and in IBD to loss of the epithelial barrier, intestinal inflammation, and the development of intestinal strictures and fistulae in Crohn’s disease. Fibroblasts have also been associated with non-response to current biologic therapies in RA and IBD. Targeting pathogenic fibroblast populations using new therapeutic modalities such as Chimeric Antigen Receptor (CAR) T-cell therapies may ‘reset’ the stroma back to health and give hope for cure in these debilitating IMIDs.
- 11 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessTargeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?
Fibroblasts constitute a major component of our stroma, the supportive bedding in which our tissues reside. The introduction of advanced single-cell technologies has greatly enhanced our appreciation of fibroblast heterogeneity in health and immune-mediated inflammatory diseases (IMIDs). This heterogeneity correlates with their diverse functions, including providing architectural support, tissue identity, ‘stromal memory’, and regulating immune responses and fibrosis. In RA, fibroblasts contribute to both synovial inflammation and bone and cartilage damage, and in IBD to loss of the epithelial barrier, intestinal inflammation, and the development of intestinal strictures and fistulae in Crohn’s disease. Fibroblasts have also been associated with non-response to current biologic therapies in RA and IBD. Targeting pathogenic fibroblast populations using new therapeutic modalities such as Chimeric Antigen Receptor (CAR) T-cell therapies may ‘reset’ the stroma back to health and give hope for cure in these debilitating IMIDs.
- Open Access
Fibroblast–Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) – an observational study protocol
Introduction: Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease-modifying antirheumatic drugs has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation, leading to increased perception of pain. Synovial stromal cells, such as fibroblasts, are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 and nerve growth factor at the messenger RNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sub-lining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis: FiND-Pain RA is a multicentre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London, and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient-reported outcome measures, ultrasound examination and ultrasound-guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sub-lining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterised. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of leukaemia inhibitory factor, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination: The study is a sub-study of the PUMIA (Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis) study, which has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.
Open AccessFibroblast–Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) – an observational study protocol
Introduction: Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease-modifying antirheumatic drugs has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation, leading to increased perception of pain. Synovial stromal cells, such as fibroblasts, are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 and nerve growth factor at the messenger RNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sub-lining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis: FiND-Pain RA is a multicentre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London, and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient-reported outcome measures, ultrasound examination and ultrasound-guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sub-lining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterised. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of leukaemia inhibitory factor, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination: The study is a sub-study of the PUMIA (Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis) study, which has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.